Bayer (BAYN) PT Set at €56.00 by Nord/LB
Bayer (FRA:BAYN) received a €56.00 ($65.12) price target from equities research analysts at Nord/LB in a research report issued on Thursday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s target price would suggest a potential upside of 0.27% from the company’s previous close.
Several other equities analysts have also recently issued reports on BAYN. UBS Group set a €110.00 ($127.91) target price on Bayer and gave the company a “buy” rating in a research note on Thursday. Goldman Sachs Group set a €77.00 ($89.53) price target on Bayer and gave the stock a “buy” rating in a research note on Tuesday. Kepler Capital Markets set a €70.00 ($81.40) price target on Bayer and gave the stock a “neutral” rating in a research note on Monday. Warburg Research set a €69.00 ($80.23) price target on Bayer and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. Finally, DZ Bank reaffirmed a “neutral” rating on shares of Bayer in a research note on Wednesday, March 20th. Ten research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of €86.17 ($100.20).
BAYN opened at €55.85 ($64.94) on Thursday. Bayer has a 52-week low of €91.58 ($106.49) and a 52-week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: How accurate is the Rule of 72?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.